Entest BioMedical, Inc. Sees Substantial Opportunities In Treatment Of Chronic Obstructive Pulmonary Disease David Koos, Chairman and CEO of Entest BioMedical, Inc. (OTCBB: ENTB), stated that the Company's unique treatments for Chronic Obstructive Pulmonary Disease (COPD), currently in development, can lead to substantial revenue opportunities. According to Koos, "Current treatment for COPD is aimed at improving quality of life, not curing the illness. It is Entest's goal to reverse the damage from COPD.
